Riociguat for pulmonary hypertension - A glass half full

New England Journal of Medicine

Volumn 369, Issue 4, 2013, Pages 386-388

  Archer, Stephen L ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; CYCLIC GMP; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTANOID; RIOCIGUAT; SILDENAFIL; TADALAFIL;

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DRUG EFFICACY; DYSPNEA; EDITORIAL; ENDARTERECTOMY; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY ENDARTERECTOMY; PULMONARY HYPERTENSION; QUALITY OF LIFE;

EID: 84880705062     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1306684     Document Type: Editorial

References (15)

1. Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-29.
2. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
3. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-66.
4. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg- Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-87.
5. Ryan JJ, Rich S, Archer SL. Pulmonary endarterectomy surgery - a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. Can J Cardiol 2011;27:671-4.
6. Thistlethwaite PA, Kemp A, Du L, Madani MM, Jamieson SW. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006;131:307-13. (Pubitemid 43121551)
7. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007; 49:1128-33. (Pubitemid 351664312)
8. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine - and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-7. (Pubitemid 28489002)
9. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract 2012;2012:290805.
10. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361:1864-71.
11. Nagendran J, Sutendra G, Paterson I, et al. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 2013;112:347-54.
12. van der Plas MN, Surie S, Reesink HJ, van Steenwijk RP, Kloek JJ, Bresser P. Longitudinal follow-up of six-minute walk distance after pulmonary endarterectomy. Ann Thorac Surg 2011;91:1094-9.
13. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894- 903. [Erratum, Circulation 2011;124(10):e279.]
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. [Erratum, N Engl J Med 2002;346:1258.] (Pubitemid 34984638)
15. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. [Erratum, N Engl J Med 2006;354:2400-1.] (Pubitemid 41653106)